Lynne Peterson is the Senior Writer for Trends-in-Medicine.

Here is the medical news to watch for June 21-27, 2021.

Emergency medicine: The American Academy of Emergency Medicine (AAEM) hybrid meeting is continuing through June 24.

Endocrinology: The American Diabetes Association (ADA) Scientific Sessions will take place virtually June 25-29. Among the things to watch besides insulin pumps and continuous glucose monitors are:

  • The results of the Phase II DARE-19 trial of an SGLT2 inhibitor – AstraZeneca’s Farxiga (dapagliflozin) – in patients with Type 2 diabetes and Covid-19.
  • Data on Zealand Pharma’s dasiglucagon, a glucagon analog.
  • Data on a protein/peptide formulation – Adocia’s M1Pram (AD-009), a bihormonal treatment for Type 1 diabetes.
  • ViaCyte’s VC-02, a stem cell-derived islet replacement therapy for Type 1 diabetes.

Hepatology: The European Association for the Study of the Liver (EASL) International Liver Congress (ILC) will take place virtually June 23-26. As usual, the key (but not only) topics will be hepatitis, non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma. Among the data to watch:

  • Additional results from a Phase IIa trial of Akero Therapeutics’ efruxifermin, an Fc-FGF21 fusion protein, in NASH.
  • Phase II initial results for Vir Biotechnology’s VIR-2218, an X-targeting RNAi therapeutic, in chronic hepatitis B virus (HBV).
  • Additional Phase Ib results on Durect’s DUR-928, a DNMTs inhibitor, in NASH.
  • A Phase IIb subgroup analysis of Inventiva Pharma’s lanifibranor, a PPAR agonist, in NASH.

Infectious diseases: The World Microbe Forum, a virtual collaboration between the American Society for Microbiology (ASM) and the Federation of European Microbiological Societies (FEMS), is continuing through June 24.

Life sciences: The Drug Information Association (DIA) virtual meeting will start June 27 and continue through July 1, bringing together patients, industry, regulators, and academics from all points in the product lifecycle and from more than 50 countries. The goal is to be a catalyst for thoughtful dialogue and debate about the intersection of science, healthcare, and regulation.

Nephrology: The Polycystic Kidney Disease (PKD) Foundation’s CON:NECT conference will take place virtually June 25-26. Attendance is free this year. Discover the latest in research and treatment options as well as the latest on dialysis, transplantation, nutrition, family planning, pain management, caregiving, and more.


  • The virtual European Academy of Neurology (EAN) meeting continues through June 22.
  • The second part of the Peripheral Nerve Society (PNS) meeting will take place virtually June 25-27. Look for the initial results of a Phase I study of a gene-editing therapy, Intellia Therapeutics’ NTLA-2001, in transthyretin amyloidosis (ATTR).


  • The virtual International Conference on Malignant Lymphoma is continuing through June 22. On that last day, watch for the results of a Phase II trial of an anti-KIR3DL2, Innate Pharma’s lacutamab (IPH-4102), in mycosis fungoides and Sézary syndrome.
  • The FDA’s Oncologic Drugs Advisory Committee (ODAC) will meet virtually on June 24 to review a PD-1 inhibitor, Incyte’s retifanlimab (MGA-012), to treat adults with locally advanced/metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or are intolerant of platinum-based chemotherapy.

Pain: American Society of Interventional Pain Physicians (ASIPP) meeting is still scheduled to be held in person in New Orleans June 24-26.

Rare diseases

  • The Prader-Willi Syndrome Association (PWSA) USA National Convention will take place virtually June 22-26. Among the data to be presented are the results of a Phase II trial of Radius Health’s RAD-011 in Prader-Willi syndrome.
  • The FSHD International Research Congress will meet virtually June 24-25. Look for top-line data from the Phase IIb ReDUX4 trial of Fulcrum Therapeutics’ losmapimod in facioscapulohumeral muscular dystrophy.


  • The FDA is holding a virtual public workshop on generic drugs on June 23 to provide an overview of the status of current science and research initiatives and to seek public input on those initiatives. FDA Acting Commissioner Janet Woodcock, MD, will be the plenary speaker. The FDA is seeking input in five key areas: formulation differences in injectables, generic oligonucleotide products (e.g., siRNAs), artificial intelligence, simulation/modeling, and bioequivalence.
  • The FDA’s Office of Medical Device and Radiological Health Operations is hosting a limited attendance virtual conference on June 23 to educate attendees about current FDA operations, such as remote regulatory assessment, postmarket risk management, the unique device identifier (UDI) program, and more.

Rheumatology: The FDA and the Arthritis Foundation are jointly hosting an Osteoarthritis Drug Development virtual workshop on June 22 on ways to expedite the development of safe and effective treatments with long-term benefits in osteo-arthritis. The objectives include identifying promising innovations, trial designs, trial endpoints, and biomarkers that will facilitate trials.

Lynne Peterson, Contributing Writer, Senior Writer for Trends-in-Medicine

Cat ID: 725

Topic ID: 88,725,254,393,730,13,182,187,111,899,935,190,127,130,725,158